It's yet another example of a Boston-area biotechnology company rushing through an open IPO window.If the company does go public, it will follow other recent local entrants Watertown-based Enanta Pharmaceuticals and Tetraphase Pharmaceuticals, and Cambridge-based Epizyme, Agios Pharmaceuticals and bluebird bio.

Foundation Medicine has developed a comprehensive cancer diagnostics solution, Foundation One, which uses genomic information to match patients with targeted treatments. The company recently presented data showing that its test has detected HER2 mutations, commonly associated with breast cancer, in 14 different types of cancer. This means drugs approved to do battle with this mutation could benefit many more patients.

Foundation said all of the shares to be sold in the proposed offering will be offered by Foundation Medicine. Goldman, Sachs & Co. and J.P. Morgan Securities, LLC will act as joint book-running managers of the offering.

Foundation Medicine was launched by Boston-based venture capital firm Third Rock Ventures and is also backed by Kleiner Perkins Caufield & Byers and Google Ventures. In January, the company said that Bill Gates and Russian Internet billionaire Yuri Milner are among the company’s $13.5 million addition to its Series B round. The investment, which also included jVen Capital managing member Evan Jones, brought the round to $56 million.